Pediatric brain tumor
Full title: Toxicities and survival outcomes of proton beam craniospinal irradiation (P-CSI) for pediatric brain tumor
Trial status: Recruiting
First posted: Feb 14, 2023
Last updated: Feb 14, 2023
Objective:
Primary objective:
-
- To evaluate the rate and severity of neutropenia in pediatric CNS tumor who receive P-CSI
Secondary objective:
-
- To evaluate the rates and severities of other acute hematologic toxicities in pediatric CNS tumor who receive P-CSI
- To evaluate the rates and severities of acute non-hematologic toxicities and late toxicities in pediatric CNS tumor who receive P-CSI
- To evaluate the rates of local control, event free survival (EFS), progression free survival (PFS) overall survival (OS) and median survival (MS) in each type of pediatric CNS tumor who receive P-CSI
- To evaluate quality of life of pediatric brain tumor patients who receive P-CSI
Sample size: 60 patients
Inclusion criteria:
- Thai children (1-15 year)
- Diagnosed with pediatric brain tumor as follows.
Embryonal tumor (Medulloblastoma, PNET, ATRT, Pineoblastoma), Ependymoma with intracranial or spinal metastasis, Pure germ cell tumor with intracranial or spinal metastasis, Non-germinomatous germ cell tumor - ECOG 0-2
Exclusion criteria
- Not receive maximal safe resection prior to radiation for embryonal tumor and ependymoma.
- No MRI spine images
- No CSF cytology report
- Unable to have follow up visits at King Chulalongkorn Memorial hospital
Phase: 2
Disease: Pediatric brain tumor
Principle investigator: Adjunct Asst. Prof. Chonnipa Nantavithya, M.D.
Co-investigator:
- Assoc. Prof. Kanjana Shotelersuk, M.D.
- Anussara Prayongrat, M.D., Ph.D.
- Asst. Prof. Kitwadee Saksornchai, M.D.
- Thitiporn Jaruthien, M.D.
- Asst. Prof. Piti Techavichit, M.D.
Location: King Chulalongkorn Memorial Hospital